Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04603807 |
| Consolidated Lead Sponsor | Roche / Genentech |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 217 participants (ACTUAL) |
| Registered Start Date | 2021-09-30 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Jilin Cancer Hospital | Changchun, China | Open Hospital Dossier -> |
| The Second Xiangya Hospital of Central South University | Changsha, China | Open Hospital Dossier -> |
| Hunan Cancer Hospital | Changsha, China | Open Hospital Dossier -> |
| West China Hospital,Sichuan University | Chengdu, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.